BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16875718)

  • 1. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.
    Chung HH; Kim MK; Kim JW; Park NH; Song YS; Kang SB; Lee HP
    Gynecol Oncol; 2006 Dec; 103(3):1031-7. PubMed ID: 16875718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
    Kim K; Kang SB; Chung HH; Kim JW; Park NH; Song YS
    Gynecol Oncol; 2008 Dec; 111(3):509-15. PubMed ID: 18851872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report.
    Fuso L; Mazzola S; Marocco F; Ferrero A; Dompè D; Carus AP; Zola P
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S187-91. PubMed ID: 16185756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of bulky stage IB and IA cervical cancer patients treated by radical hysterectomy with and without neoadjuvant chemotherapy: long-term follow-up.
    Manusirivithaya S; Chareoniam V; Pantusart A; Isariyodom P; Srisomboon J
    J Med Assoc Thai; 2001 Nov; 84(11):1550-7. PubMed ID: 11853297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of GGH -401C>T polymorphism on cisplatin-based chemoradiotherapy response and survival in cervical cancer.
    Silva IH; Nogueira-Silva C; Figueiredo T; Lombo L; Faustino I; Catarino R; Nogueira A; Pereira D; Medeiros R
    Gene; 2013 Jan; 512(2):247-50. PubMed ID: 23107767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma.
    Choi CH; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
    Gynecol Oncol; 2007 Jan; 104(1):64-9. PubMed ID: 16904170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects.
    Niwa Y; Matsuo K; Ito H; Hirose K; Tajima K; Nakanishi T; Nawa A; Kuzuya K; Tamakoshi A; Hamajima N
    Gynecol Oncol; 2005 Oct; 99(1):43-9. PubMed ID: 15990162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.
    Kim YB; Cho JH; Keum KC; Lee CG; Seong J; Suh CO; Kim GE
    Gynecol Oncol; 2007 Jan; 104(1):58-63. PubMed ID: 16919718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.
    Choi CH; Song SY; Choi JJ; Park YA; Kang H; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
    BMC Cancer; 2008 Oct; 8():295. PubMed ID: 18847499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients.
    Figl A; Scherer D; Nagore E; Bermejo JL; Dickes E; Thirumaran RK; Gast A; Hemminki K; Kumar R; Schadendorf D
    Mutat Res; 2009 Feb; 661(1-2):78-84. PubMed ID: 19073198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
    Chen H; Liang C; Zhang L; Huang S; Wu X
    Gynecol Oncol; 2008 Sep; 110(3):308-15. PubMed ID: 18606439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer.
    Moreno V; Gemignani F; Landi S; Gioia-Patricola L; Chabrier A; Blanco I; González S; Guino E; Capellà G; Canzian F
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2101-8. PubMed ID: 16609022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neoadjuvant chemotherapy with intra-arterial infusion in the treatment of advanced cervical cancer].
    Mizuno K; Kidokoro K; Miyazaki K; Yoshida K; Nakagawa A; Mizuno M; Suzuki S; Kuno N; Furuhashi M; Ishizuka T; Ishikawa K
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):815-9. PubMed ID: 15984522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion.
    Huguet F; Cojocariu OM; Levy P; Lefranc JP; Darai E; Jannet D; Ansquer Y; Lhuillier PE; Benifla JL; Seince N; Touboul E
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1508-15. PubMed ID: 18676093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.